U.S. markets closed

Axcella Health Inc. (AXLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.65+0.23 (+2.21%)
At close: 04:00PM EDT
10.81 +0.16 (+1.50%)
After hours: 07:05PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close10.42
Bid10.27 x 900
Ask10.98 x 1200
Day's Range10.06 - 11.00
52 Week Range2.59 - 47.75
Avg. Volume956,948
Market Cap31.393M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-18.22
Earnings DateOct 30, 2023 - Nov 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est192.66
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AXLA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Axcella Health Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • InvestorPlace

    Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now

    The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive. Therefore, it is extraordinarily common to find heavily indebted firms that incur massive losses when investing in the sector. That’s essentially the MO for all of the biotechnology industry: Spend a lot of money for a chance at even greater sums of money and hope you don’t flame out. The numbers don’t lie, though, and

  • Zacks

    Are Medical Stocks Lagging Axcella Health (AXLA) This Year?

    Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

  • Business Wire

    Axcella Announces Reverse Stock Split Effective September 19, 2023

    CAMBRIDGE, Mass., September 14, 2023--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The